24KIT
Roche joins CGM race
At the 17th International Conference on Advanced
Technologies and Treatments for Diabetes (ATTD) held
March 2024, Roche shared recent accuracy data for
its new Accu-Chek SmartGuide solution for real-time
continuous glucose monitoring.
Roche's CGM solution
consists of a CGM sensor
and two apps designed to
display current glucose
values and predictions over both 30
minutes and two hours. In addition,
it features a risk prediction for
nocturnal hypoglycemia.
In early July 2024, Roche obtained
CE mark accreditation for the AccuChek SmartGuide
device and will
shortly start to launch the solution
initially in selected European
countries, then more broadly.
During the company's symposium
(see photo) at ATTD chaired
by Professor Chantal Mathieu
(University of Leuven, Belgium)
and Professor Francesco Giorgino
(University of Bari, Italy), recent
accuracy and performance data
of the new CGM solution were
shared. Despite the advancements
made in diabetes therapy and the
increased uptake of technology
over recent years, still only 55-60%
of people with diabetes reach their
therapy goals.1,2
This underlines the many unmet
needs and challenges people
with diabetes have in the daily
management of their condition.
At the event, Professor Pratik
Choudhary (University of Leicester,
UK) said, "Fear of hypoglycaemia,
hypoglycaemia unawareness, sleep
disruption, intrusion in daily life and
distress caused by device alarms and
alerts are just some examples of the
many daily challenges a person with
diabetes faces."
The Accu-Chek SmartGuide
CGM solution aims to address these
unmet needs. Study evidence and
participants' feedback presented by
Professor Julia Mader (University of
Graz, Austria), underscore the sound
performance, accuracy and safety
of the sensor. The study included 48
people with Type 1 or Type 2 diabetes
wearing three sensors for a period
of 14 days each. The study results
showed a high system accuracy with
an overall mean absolute relative
deviation (MARD, a measure of
accuracy) of 9.2% and 99.8% of the
measured glucose values in zones A
and B on the Parkes Error Grid.3 "The
Accu-Chek SmartGuide solution is
not only highly accurate and robust
in its performance in a clinical
setting, but also during routine day
evaluation", illustrated Professor
Mader, "In addition, 83% of our study
participants liked or very much liked
the Accu-Chek SmartGuide CGM
device and about 80% liked or very
much liked the app design."
Predictive insights
In the symposium, the Accu-Chek
SmartGuide CGM solution was
demonstrated to provide users with
predictive insights ahead of time.